Table 2 Results.
From: Effect of oral zinc regimens on human hepatic copper content: a randomized intervention study
Zinc acetate 50 mg × 3 (n = 10) | Zinc acetate 150 mg × 1 (n = 9) | Zinc gluconate 50 mg × 3 (n = 9) | Zinc gluconate 150 mg × 1 (n = 9) | ||
|---|---|---|---|---|---|
Amount of hepatic copper-64 on end-of-treatment compared to baseline scan (%) | 56 (37) | 56 (33) | 49 (21) | 85 (40) | NS |
Baseline SUV1 | 12.3 (3.2) | 15.5 (4.5) | 17.0 (2.4) | 13.2 (2.9) | P = 0.02 |
End-of-treatment SUV1 | 6.2 (1.9) | 8.2 (4.7) | 8.2 (2.8) | 10.4 (3.4) | NS |
Baseline %AD2 | 26.9 (7.5) | 33.1 (9.0) | 35.8 (4.4) | 28.1 (6.7) | P = 0.02 |
End-of-treatment %AD2 | 13.3 (5.6) | 17.8 (10.3) | 17.4 (7.5) | 22.0 (6.7) | NS |
Adherence violations | 0 | 4 | 0 | 0 | |
Fasting violations | 2 | 1 | 2 | 0 | |
Adverse events possibly related to trial drug | |||||
Gastric discomfort | 2 | 4 | 0 | 1 | P = 0.001 |
Nausea | 5 | 5 | 1 | 2 | |
Headache | 0 | 2 | 0 | 0 | |
Palpitation | 0 | 1 | 0 | 0 | |
Obstipation | 0 | 2 | 0 | 0 | |
Total events | 7 | 15 | 1 | 3 | |
(n = 5) | (n = 5) | (n = 9) | (n = 4) | ||
|---|---|---|---|---|---|
Serum zinc3 (µmol/L) | |||||
Normal range 10–19 µmol/L | 25.2 (5.0) | 20.4 (4.0) | 18.9 (4.3) | 17.3 (1.5) | P = 0.04 |
